Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study

Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study

Adino Tesfahun Tsegaye^1,&, Wagaye Alemu², Tadesse Awoke Ayele¹

 

¹Department of Epidemiology and Biostatistics, University of Gondar, College of Medicine and Health Sciences, Institute of Public Health, Gondar, Ethiopia, ²Department of Epidemiology and Biostatistics Ethiopia, Dilla University, College of Medicine and Health Sciences, Dilla, Ethiopia

 

 

^&Corresponding author
Adino Tesfahun Tsegaye, Department of Epidemiology and Biostatistics, University of Gondar, College of Medicine and Health Sciences, Institute of Public Health, Gondar, Ethiopia

 

 

 

 

Acquired Immune Deficiency Syndrome (AIDS), which is caused by the Human Immunodeficiency Virus (HIV), has been the major public health problem worldwide [1]. The majority of HIV infected individuals live in sub-Saharan Africa (SSA) [2]. In these countries, AIDS-related morbidity and mortality remain the highest in the world because of limited access to HIV diagnosis and treatment. According to the 2012 UNAIDS report, around 1.7 million people died from AIDS-related causes worldwide, and 70% occurred in SSA [3]. Ethiopia is one of the hardest hit sub-Saharan African countries by the HIV pandemic with an estimated death of 52,405 by 2014 [4]. Since the introduction of Zidovudine (ZDV) in 1987 as a first antiretroviral drug, there have been significant advancements in the antiretroviral treatment [5]. Currently, there are six classes of antiretroviral drugs such as Nucleoside reverse transcriptase inhibitors (NRTIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Protease inhibitors (PIs), Integrase inhibitors (IIs), Fusion inhibitors (FIs), and Chemokine receptor antagonists (CRAs) [5]. For a new patient who is going to start ART, a combination of three drugs is provided. The drug combination contains two NRTIs and one NNRTIs [6]. After highly active antiretroviral treatment (HAART) introduced in 1995-96, HIV infection turns from inevitable fatal condition into chronic manageable disease [7]. In recent years, efforts have been made to expand access to ART in low-income countries, and it is showing encouraging results [8-11]. The benefit of ART in restoring immune function and reducing HIV related morbidity and mortality is lost when a patient develops treatment failure [12, 13]. This happens when a patient has poor adherence, drug resistance, high baseline plasma viral load, and low baseline CD4 count [14-19]. Following a failure of the first-line regimen, patients switch to a second-line regimen containing two new NRTIs and one PI [6, 20, 21]. Since third-line regimens are costly and not readily available in resource-limited countries, second-line regimens are often the last therapeutic option available for patients in these settings [22]. Not all patients who initiate antiretroviral therapy respond well. Some patients may not respond due to poor adherence, suboptimal antiretroviral treatment potency, and genetic mutation of HIV strains [23]; this could be followed by death. Since living longer with HIV is one of the global strategies, provision of ART by itself is not enough to control the problems of HIV treatment; rather its therapeutic effect on improving survival needs thorough monitoring and evaluation through scientific research. Though some studies based in Ethiopia investigate the outcomes of first-line HIV treatment; little has been done regarding second-line treatment. Therefore this study aimed to measure the incidence and determinants of mortality after a switch to second-line ART regimens.

 

 

Study design and setting: a multi-center institution-based retrospective follow-up study was conducted in eight selected governmental hospital found in Amhara regional state, Ethiopia. Five referral hospitals (Dessie, Bahirdar (Felegehiwot), Debremarkos, University of Gondar, and Debre Birhan Referral Hospitals) and three general hospitals (Finote Selam, Woldiya, and Debretabor General Hospitals) were included in this study. The hospitals were selected purposively based on their representativeness to the people of the Amhara regional state. Almost all bigger hospitals which provide second-line ART in the region were included. All of the hospitals initiated ART in 2005. By 2014, there were more than 220,000 people who ever enrolled in HIV care and 102,088 current ART users in the region. Among the ART users, 1.5% of them were on second-line ART [24]. In accordance with the current recommendation, reverse transcriptase inhibitors (NRTI) such as lamivudine (3TC), zidovudine (AZT), and tenofovir (TDF); non-nucleoside reverse transcriptase inhibitors (NNRTI) such as efavirenz (EFV), nevirapine (NVP); and protease inhibitors (PI) such as atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r) were used. For first-line treatment, a combination of two NRTIs with one NNRTI, and for second-line treatment two NRTIs with one PI [25, 26] was used. At each visit, patients' clinical condition including the WHO clinical stage, functional status, weight, and medication adherence were assessed by the providers. The CD4 count was measured at baseline and every six months or when indicated. According to the current practice, if the patients develop treatment failure of first-line ART (clinical, immunological, or virological), they switch to second-line ART.

 

Participants: the study population was adult HIV patients aged above 15 years who started second-line ART in the selected hospitals between February 2008 and January 2016. The data were extracted from February to April 2016. Patients who initiated second-line therapy in the selected hospitals with a documented failure of first-line therapy were included, and patients who transferred in after started second-line treatment in other places were excluded. Initially, the calculated sample size was 1024. However, from our preliminary assessment, we found 1233 patients who fulfilled our inclusion criteria and we have included all of them in the study. In the actual data collection, 41 of them had an incomplete record which couldn't able us to entertain their outcome and they were excluded in the final model. Finally, 1192 patient records were used for the final analysis. Data were collected from medical records, registers, and computer database. Twenty trained ART nurses collected the data using a pretested data collection checklist under the supervision of 5 public health professionals who had a Master of Public Health (MPH). The collected data were checked on a daily bases for consistency, completeness, and accuracy; appropriate corrections were made.

 

Variables of the study: the primary outcome variable was time to death. It was defined as the death of a patient while on second-line ART. Its incidence was measured by using person-time at risk starting from the time of switch to a second-line regimen until each patient ended follow-up. The independent variables were socio-demographic factors (sex, age, educational status, environmental factors (health facility), occupation) and clinical and treatment-related factors (body mass index, CD4 count, CPT, IPT, functional status, WHO clinical stage, opportunistic infections, presence of severe side effects, presence of active TB, adherence, ART drug regimen, duration of treatment, regimen modification). Transferred out refers to patients who are transferred to other health care facilities. A loss to follow-up (LTFU) was defined as a patient who did not receive ART refills for a period of three months or longer and is not yet classified as "dead" or "transferred-out". Patients were considered censored if they transferred out, lost to follow up or remain on follow up at the end of the study. The clinical adherence of participants was assessed and it was defined as a regular attendance of patients according to a given appointment. If the patients were coming regularly by the given appointment dates in >85% of the times, they were considered as having good clinical adherence, and <85% attendance as poor clinical adherence [25, 26].

 

Statistical analysis: the collected data were entered using EPI-INFO version 7.00 and then exported to STATA version 12.0 for further analysis. A life table was used to estimate the cumulative survival of patients; Kaplan Meier failure curve was used to estimate mortality rate, and a log-rank test was used to compare failure curves between the different categories of the explanatory variables. Schoenfeld residuals test (both global and scaled) and graphical methods were used to check Cox proportional hazards assumption. The P-value for the global test was 0.1 (not significant), which indicates the model was fit. Cox proportional hazards model was used to identify determinants of mortality. Variables having a p-value of 0.2 or less in the bi-variable analysis were fitted into the multivariable model. Ninety-five percent confidence interval of hazard ratio (HR) was computed and variables having a p-value less than 0.05 in the multivariable Cox proportional hazards model were considered as statistically significant.

 

Ethics consideration: ethical clearance was obtained from the institutional review board (IRB) of the University of Gondar. A letter of support and a permission letter were obtained from the Amhara Regional State Health Bureau and the hospital's administration respectively. All patient records were de-identified and kept locked. Since we were reviewed patient records, informed consent was waived.

 

 

Baseline characteristics of the study participants: out of 1192 samples included in the final analysis, 387 (32.5 %) were from Dessie referral hospital followed by Felegehiwot referral hospital (378 (31.7 %)). The median age of patients at the start of antiretroviral treatment was 32 years with an Interquartile range (IQR) of 11 years, and the majority of the patients 609 (51.1 %) were males (Table 1). With regard to their duration of stay on first-line ART, 348 (29.2 %) of patients stayed 12 to 36 months, and 101 (8.5 %) of patients stayed less than 12 months. Before switching to a second-line regimen, regimens were modified for 535 (43.85 %) participants and among them, it was modified only once for 423 (79.07%), two times for 100 (18.69%) and three times and above for 12 (2.24%) patients. Majority of the patients (541 (46.24%)) switched to second-line ART regimen because of immunological failure of first-line treatment (Table 1). Regarding the regimen they take, 406 (33.17%) used TDF_3TC_LPV/r and 201(16.47%) of patients used the drug combination ABC-ddi-LPV/r (Table 2). The majority (929 (77.9 %)) had a clinical adherence level of < 85%; 379 (31.8%) had a base-line CD4 count of <=50 cells/mm³; 843 (70.7%) were given cotrimoxazole; and 277 (23.2%) received isoniazid (INH) preventive therapies.

 

Mortality after switching to second-line ART: among 1192 adult HIV-infected patients on second-line ART, 136 (11.41%) died; out of them, 56 (41.17%) died within 12 months after switching to second-line treatment. The mean follow-up time of patients on first-line ART was 49.51 months (SD ± 28.18). The median follow-up time on second-line ART was 25.3 months (IQR 34.66). The study cohort had contributed a total of 3157 person-years of follow-up. Over the study period, the total mortality rate was 4.33 per 100 person-years. The mortality rate of patients at the end of the 12^th month after switching to second-line ART was 39.6 per 1000 person-years, 24 per 1000 person-years at 36^th month, 8 per 1000 person-years at the 72^nd month, and 2 per 1000 person-years at 96^th month (Figure 1). The incidence of mortality among INH users was 7.4 per 1000 person-years and among non-users was 51.3 per 1000 person-years (p-value <0.000) (Figure 2). The incidence of mortality in patients who had good clinical adherence was 18 per 1000 person-years and it was 50 per 1000 person-years in those who had poor clinical adherence (p-value = 0.0003) (Figure 3).

 

Factors associated with mortality of HIV positive patients on second-line ART: in the bivariable Cox proportional hazard analysis; educational status, baseline functional status, WHO clinical stage at the switch, INH prophylaxis, the reason of eligibility to ART, second-line regimen modification, and adherence were statistically significant. Variables such as age, baseline CD4 count, facility type, the reason of switch to a second-line regimen, gender, occupation, baseline BMI, and past TB treatment had a P-value of >0.2 in the bivariable model and were not included in the multivariable model. In the multivariable Cox regression analysis, the independent predictors of mortality were not taking INH preventive therapy (AHR: 6.9; 95% CI: (3.0, 15.7)), did not make modification on second-line regimen (AHR: 4.8; 95% CI: (3.1, 7.5)), poor clinical adherence (AHR: 2.6; 95% CI: (1.4, 4.6)), functional status of bedridden (AHR: 3.0; 95CI (1.7, 5.5)), and having attained of tertiary education (AHR: 0.4; 95%CI: (0.2, 0.9)) (Table 3). The second-line regimen modification, tertiary education, functional status of working, good adherence and using INH prophylaxis had protective effects on mortality of patients. The risk of death was 4.8 times higher for those patients with second-line regimen was not modified as compared to those with second-line regimen modified. The rate of mortality was 3 times higher among those who were bedridden at the switch to a second-line regimen compared with those who were working. The risk of death was 2.6 times higher for patients who had poor clinical adherence compared with those with good clinical adherence. Patients who had tertiary education were 60% less likely to die than those patients who had no formal education. Patients who did not take INH were 6.9 times at higher risk of death compared with those who did take INH.

 

 

This study aimed to measure mortality and its determinants among HIV infected adult patients on second-line antiretroviral therapy. The incidence of mortality was 4.33 per 100 person-years; which is consistent with studies done in India, in resource-limited countries and in sub-Saharan African countries [27-29]. However, it is higher than studies done in Zambia [30] and Switzerland [31]. The higher rate of mortality in this study might be due to the fact that most patients had advanced disease at baseline (CD4 count ≤200 cells/mm³); that could lead them to have bad outcomes [29]. The delay to switch to second-line regimens, that usually happens in resource-limited settings, might explain the higher mortality [32]. Different factors have been identified as determinants of mortality of patients on second-line ART. In the multivariable analysis: INH, second-line regimen modification, clinical adherence, functional, and educational status were found statistically significant determinants of mortality. Patients who had a history of second-line regimen modification after the switch had a lower risk of death than those had not. This is similar to a study done in resource-limited countries [28]. Patients who had modified their regimen might get better follow up and get their problems managed early. In addition, since deferring a drug modification while it is required might have a negative implication of accumulation of drug resistance [33], these groups of patients might be benefited by the regiment modification which could help them to overcome an emerging drug resistance that could be a potential cause for lower immunity and death. Having good clinical adherence was protective of mortality. This evidence is supported by previously done researches [34, 35]. Having good clinical adherence, patients wouldn't discontinue their drugs, have close follow up and counseling form the health care providers, and they might be also psychologically stable to take their treatment. Due to these reasons, bad outcomes are less likely to happen among these patients. Taking INH had a protective effect on mortality of patients. This is similar to a study done in resource-limited countries, and Ethiopia [28, 35]. As already known, TB is the commonest opportunistic infection (OI) among HIV patients and it is a potential cause of death. If an HIV patient takes INH prophylaxis, it would prevent the morbidity and mortality due to TB. Patients who were bedridden at switch were at higher risk of death. This is consistent with a finding from eastern Ethiopia [36]. Functional status of patients has a correlation with their clinical and immunological status. Usually, patients in an advanced stage of the disease are bedridden and the chance of death is higher among those people [34]. Patients who were illiterate had a high risk of mortality compared to those with tertiary education. This is similar to a study done in Addis Ababa, Somalia and Tigray regions Ethiopia [35, 37, 38]. This could be due to the reason that educated people follow their treatment appropriately and may have better health-seeking behavior for different OIs and other related diseases. The main strength of this study is its representativeness in terms of covering multiple treatment centers, and the length of follow up time which was long enough to estimate mortality. However, it has its own limitations. Considering all death as HIV related could overestimate the incidence of mortality. On the contrary, the lost to follow up patients might include individuals who died at home without being reported and that could underestimate the incidence of mortality. In addition, residual confounding could present by the absence of viral load record, under-reporting of clinical conditions, and missing laboratory results. The data were collected in a retrospective fashion using secondary sources, with resulting incompleteness.

 

 

The incidence rate of mortality was high and most of the deaths occurred within 12 months after switching to second-line ART. Higher mortality among adult HIV-infected patients was associated with poor adherence, no formal education, not taking IPT, being bedridden at the time of the switch, and not modifying second-line treatment. Improving treatment adherence of patients by providing consistent adherence counseling, providing INH prophylaxis and monitoring patient's regimen more closely during the first twelve months after switch could decrease mortality of HIV patients on a second-line regimen.

 

 

The authors declare no competing interests.

 

 

Adino Tesfahun Tsegaye and Wagaye Alemu conceptualized and designed the study and performed the data analysis and wrote the draft and final manuscripts. Tadesse Awoke Ayele provided technical research guidance. All authors designed the data collection tool and wrote and approved the final manuscript.

 

 

We would like to thank the hospitals' administrative bodies, data clerks and card room workers for their cooperation and permission to conduct the study. We are grateful to the University of Gondar for financial support as well as the data collectors who participated in this study for their commitment.

 

 

Table 1: baseline characteristics of adult HIV patients on second-line ART in Amhara region February 2008-2016

Table 2: life table for the probability of death of adult HIV patients on second-line ART in Amhara region, Ethiopia, February 2008-2016

Table 3: bivariable and multivariable Cox regression analysis of predictors of mortality on second-line ART among adult HIV patients in Amhara region, Ethiopia, February 2008-2016

Figure 1: Kaplan Meier failure curve of mortality on second-line ART among adult HIV patients in Amhara region, Ethiopia February 2008-2016

Figure 2: Kaplan Meier failure curve of mortality on second-line ART among adult HIV patients in Amhara region, Ethiopia February 2008-2016 based on isoniazid prophylaxis

Figure 3: Kaplan Meier failure curve of mortality on second-line ART among adult HIV patients in Amhara region, Ethiopia February 2008-2016 based on clinical adherence

 

 

1. Federal HIV/AIDS Prevention and Control Office (HAPCO). Country Progress Report on HIV/AIDS Response. Ethiopia. 2012.


2. WHO, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector-progress report. 2007.


3. UNAIDS. UNAIDS report on the global AIDS epidemic Joint United Nations Programme on HIV/AIDS (UNAIDS). Geneva. 2012.


4. Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA et al. Global, regional, and national incidence and mortality for HIV,tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9947): 1005-1070. PubMed | Google Scholar


5. Rathbun RC, Greenfield RA, Liedtke MD. Antiretroviral Therapy for HIV infection. Medscape. 2012. Accessed July 22 2018


6. WHO. Antiretroviral therapy: HIV/AIDS. Geneva. 2012. Accessed July 22 2018.


7. Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Ann Ist Super Sanita. 2011; 47(1): 44-48. PubMed | Google Scholar


8. Weidle PJ, Malamba S, Mwebaze R. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet. 2002 Jul 6; 360(9326): 34-40. PubMed | Google Scholar


9. Ferradini L, Katrina F Ortblad, Caterina Guinovart, Stephen SLim, Timothy M Wolock, D Allen Roberts et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005; 40(3): 336-343. Google Scholar


10. Idigbe EO, Adewole TA, Eisen G. Management of HIV-1 infection with a combination of nevirapine, stavudine and lamivudine: a preliminary report on the Nigerian antiretroviral program. Acquir Immune Defic Syndr. 2005; 40(1): 65-69. PubMed | Google Scholar


11. Renaud-Thery F, Nguimfack BD, Vitoria M. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first-and second-line regimens. AIDS. 2007 Jul; 21 Suppl 4: S89-95. PubMed | Google Scholar


12. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved Survival among HIV-Infected Patients after Initiation of Triple-Drug Antiretroviral Regimens. Canadian Medical Association. 1999; 160(5): 659-665. PubMed | Google Scholar


13. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M et al. Impact of New Antiretroviral Combination Therapies in HIV Infected Patients in Switzerland: Prospective Multicentre Study: Swiss HIV Cohort Study. BMJ. 1997 Nov 8; 315(7117): 1194-9. PubMed | Google Scholar


14. Cadosch D, Bonhoeffer S, Kouyos R. Assessing the Impact of Adherence to Anti-Retroviral Therapy on Treatment Failure and Resistance Evolution in HIV. Journal of the Royal Society, Interface/the Royal Society. 2012; 9(74): 2309-2320. PubMed | Google Scholar


15. Datay MI, Boulle A, Mant D, Yudkin P. Associations with virologic treatment failure in adults on Antiretroviral Therapy in South Africa a case-control study. Journal of Acquired Immune Deficiency Syndromes. 2010; 54(5): 489-49. PubMed | Google Scholar


16. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, Zhao Y, Dou Z et al. Predictors of Virologic Failure in HIV-1- Infected Adults Receiving First-Line Antiretroviral Therapy in 8 Provinces in China. Clinical Infectious Diseases. 2010. 50(2): 264-271. PubMed | Google Scholar


17. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J et al. Predictors of HIV Drug-Resistance Mutations in a Large Antiretroviral-Naive Cohort Initiating Triple Antiretroviral Therapy. Journal of Infectious Diseases. 2005; 191(3): 339-347. PubMed | Google Scholar


18. WHO. WHO HIV drug resistance report. Geneva, Switzerland. 2012. Google Scholar


19. Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, Chen RY. Five year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009 Aug 18; 151(4): 241-51, W-52. PubMed | Google Scholar


20. Keiser O, Tweya H, Braitstein P, Dabis F, MacPhail P, Boulle A et al. Mortality after Failure of Antiretroviral Therapy in Sub-Saharan Africa. Tropical Medicine & international Health. 2010; 15(2): 251-258. PubMed | Google Scholar


21. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A et al. Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy: results from the EuroSIDA Study Group. The Journal of Infectious Diseases. 2004; 190(11): 1947-1956. Google Scholar


22. Médecins Sans Frontières (MSF). Untangling the web of antiretroviral price reductions. 16^th ed Geneva, Switzerland: Médecins Sans Frontières, Access campaign. 2013.


23. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of inductionmaintenance therapy. JAMA. 2000; 283(2): 205-211. PubMed | Google Scholar


24. FMOH. Health Sector Development programme IV annual performance report. 2014.


25. Federal Ministry of Health Ethiopia. National Comprehensive HIV Care and Treatment Training for Health care Providers Participant Manual. 2014.


26. WHO. Consolidated Guidelines On The Use Of Antiretroviral Drugs For Treating And Preventing HIV Infection Recommendations for A publichealth Approach. 2013. Google Scholar


27. Patrikar S. Profile of HIV Patients on Second Line Antiretroviral Therapy: The Indian Experience. Department of Community Medicine, Armed Forces Medical College, Pune,: India. 2015. Google Scholar


28. Pujades-Rodríguez M, Balkan S. Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries. 2010. Google Scholar


29. Palombi L, Marazzi MC, Guidotti G. Incidence and Predictors of Death, Retention and Switch to Second-Line Regimens in Antiretroviral-Treated Patients in Sub-Saharan African Sites with Comprehensive Monitoring Availability. Clinical Infectious Diseases. 2008; 48(1): 115-122. PubMed | Google Scholar


30. Gsponer T, Petersen M, Egger M, Phiri S, Maathuis MH, Boulle A et al. The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. AIDS. 2012; 26(1): 57-65. PubMed | Google Scholar


31. Hasse B, Ladergerber B, Furrer H. Morbidity and ageing in HIV-infected persons: the Swiss HIV cohort study. Clinical Infectious Diseases. 2011; 53(11): 1130-1139. PubMed | Google Scholar


32. Petersen ML, Tran L, Geng EH, Reynolds SJ, Kambugu A, Wood R et al. Delayed Switch of Antiretroviral Therapy after Virologic Failure Associated with Elevated Mortality among HIV-infected Adults in Africa. AIDS. 2014; 28(14): 2097-2107. PubMed | Google Scholar


33. Zhou J, Li PC, Kumarasamy N, Boyd M, Chen YM, Sirisanthana T et al. Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD). HIV Med. 2010; 11(1): 31-39. PubMed | Google Scholar


34. Ayalew MB. Mortality and Its Predictors among HIV Infected Patients Taking Antiretroviral Treatment in Ethiopia: A Systematic Review. AIDS Research and Treatment. 2017; 5415298: 1-10. PubMed | Google Scholar


35. Edessa D, Likisa J. A description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: ACohort Study. PLoSONE. 2015; 10(9): e0137492. PubMed | Google Scholar


36. Biadgilign S, Reda AA, Digaffe T. Predictors of mortality among HIV infected patients taking antiretroviral treatment in Ethiopia: a retrospective cohort study AIDS Research and Therapy. 2012; 9(15). Google Scholar


37. Tadesse K, Haile F, Hiruy N. Predictors of Mortality among Patients Enrolled on Antiretroviral Therapy in Aksum Hospital, Northern Ethiopia: a retrospective cohort study. PLoS ONE. 2014; 9(1): e87392. PubMed | Google Scholar


38. Damtew B, Mengistie B Alemayehu T. Survival and Determinants of Mortality in Adult HIV/AIDS Patients Initiating Antiretroviral Therapy in Somali Region, Eastern Ethiopia. Pan Afr Med J. 2015 Oct 14; 22: 138. PubMed | Google Scholar